Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1169
- Registration Number
- NCT02008357
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸University of Kansas Hospital, Fairway, Kansas, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of Axiron® in Healthy Participants
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT02004132
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Nasal GlucagonDrug: Intramuscular Glucagon
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT01997411
- Locations
- 🇺🇸
Barbara Davis Center for Diabetes, Aurora, Colorado, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Intramuscular GlucagonDrug: Nasal Glucagon
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 77
- Registration Number
- NCT01994746
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Barbara Davis Center for Diabetes, Aurora, Colorado, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo - CapsuleDrug: LY3108743 - CapsuleDrug: Placebo - SolutionDrug: LY3108743 - Solution
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 44
- Registration Number
- NCT01995656
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of Insulin Peglispro in Healthy Male Japanese Participants
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT01995526
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
A Study of LY2928057 in Hemodialysis Participants
- Conditions
- Kidney Disease, ChronicRenal Insufficiency, Chronic
- Interventions
- Drug: PlaceboDrug: LY2928057
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01991483
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Davita Clinical Research, DN, Lakewood, Colorado, United States
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT01983878
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of LY2801653 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [^14C]-LY2801653
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01981408
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of Baricitinib and Ciclosporin in Healthy Participants
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01968057
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom